NMN and NR Seasonal Use Considerations: What the Evidence Actually Shows

Why Seasonality Matters for NAD+ Biology

NAD+ is not a static metabolite. Its tissue concentrations rise and fall with circadian rhythm, caloric state, oxidative stress load, and, critically, the time of year. Photoperiod changes alter melatonin secretion, shift core body temperature rhythms, and modulate the transcription of NAMPT (nicotinamide phosphoribosyltransferase), the enzyme that converts nicotinamide to NMN inside cells. Short winter days suppress NAMPT in peripheral tissues, reducing the cell's own capacity to regenerate NAD+ from recycled nicotinamide. [1]

NAMPT as the Seasonal Bottleneck

NAMPT activity is tightly tied to the CLOCK/BMAL1 circadian machinery. A study published in Cell showed that NAMPT transcription oscillates with roughly 24-hour periodicity, and disrupting either CLOCK or BMAL1 attenuates the amplitude of NAD+ oscillations by approximately 50%. [2] When photoperiod compresses the light phase in winter, the phase and amplitude of NAMPT expression may shift in a direction that reduces baseline NAD+ in tissues with high turnover, such as skeletal muscle and liver.

UV-B Radiation and Cutaneous NAD+ Synthesis

Human skin synthesizes nicotinamide partly through UV-B-driven photolysis of tryptophan and through repair-driven PARP-1 activation. A high UV-B index in summer accelerates local NAD+ consumption via PARP-1 at sites of UV-induced DNA damage, while simultaneously stimulating de novo synthesis. The net effect on systemic NAD+ is person-specific. Darker Fitzpatrick skin types (IV-VI) have higher melanin density that attenuates UV-B penetration, which may reduce cutaneous NAD+ photosynthesis further in winter at northern latitudes. [3]

Metabolic Shifts Across the Calendar Year

Seasonal insulin sensitivity follows a reproducible pattern in population studies. A 2016 analysis of HbA1c data from 1.5 million U.S. Patients found that HbA1c peaks in late summer or fall and troughs in late winter, independent of diet changes. [4] Because NMN's most replicated benefit in humans, improved insulin sensitivity per Yoshino et al. 2021, operates through skeletal-muscle NAD+-SIRT1 signaling, periods of natural insulin resistance may represent windows where precursor supplementation offers greater incremental benefit. [5]

The Yoshino 2021 Trial: Baseline Evidence and Seasonal Gaps

The most rigorous human NMN trial to date remains Yoshino et al. 2021 (N=25, postmenopausal prediabetic women, 250 mg/day NMN for 10 weeks). [5] Participants showed significantly improved insulin-stimulated glucose disposal in skeletal muscle, with a rise in muscle NAD+ content and upregulation of SIRT1 and SIRT3 activity. The trial ran entirely in a single season, limiting direct conclusions about whether the benefit magnitude would differ in winter versus summer.

What the Trial Did and Did Not Measure

The Yoshino group measured skeletal-muscle RNA expression by transcriptome analysis and found upregulation of pathways related to fatty acid oxidation and mitochondrial biogenesis. They did not track circulating vitamin D, melatonin, or photoperiod exposure. That absence means the trial cannot confirm whether participants were vitamin D-replete, which matters because vitamin D receptor signaling and NAMPT promoter activity share overlapping transcriptional regulators. [6]

Dose Selection and Seasonal Scaling

The 250 mg/day dose used by Yoshino et al. Sits at the lower boundary of the dose range tested in humans. Trammell et al. 2016 (N=12 healthy adults) showed that a single oral dose of NR raised whole-blood NAD+ in a dose-proportional manner from 100 mg to 1,000 mg, with 300 mg producing a roughly 2.7-fold peak rise above baseline. [7] If NAMPT is suppressed in winter, the theoretical rationale for a 500 mg dose rather than 250 mg during short-day months is plausible, though direct seasonal dose-ranging trials have not been conducted.

Morning Versus Evening Dosing Across Seasons

Circadian alignment is a practical consideration year-round, but it becomes more operationally significant in winter when the active-phase window compresses. NAMPT mRNA expression in peripheral blood mononuclear cells peaks roughly 2 to 4 hours after wake time. [2] Taking NMN or NR in the first 30 to 60 minutes after waking delivers the substrate when the salvage pathway enzyme is maximally transcribed.

Food and Bioavailability

NMN is absorbed via the Slc12a8 transporter in the small intestine; NR uses a distinct set of nucleoside transporters. A 2020 pharmacokinetic study by Irie et al. (N=10) found that oral NMN raised plasma NMN within 2 to 3 minutes and elevated whole-blood NAD+ by 1 hour. [8] Food co-ingestion slowed peak plasma NMN by approximately 30 minutes but did not reduce the area under the curve, suggesting dosing with breakfast is reasonable for tolerability without sacrificing absorption.

Winter Morning Dosing Protocol

In winter months at latitudes above 40°N, dawn can fall after 7:00 AM. The practical recommendation from circadian-medicine principles is to dose NMN or NR within the first hour of waking regardless of clock time, pairing the dose with a meal that includes protein to support tryptophan availability for the de novo NAD+ synthesis pathway. No direct RCT has tested this specific pairing, so the recommendation carries a grade-C evidence weight by current standards.

Summer-Specific Considerations: Heat, UV, and PARP Activation

Summer introduces two competing forces on NAD+ homeostasis: higher UV-B exposure increases PARP-1-mediated consumption, and longer photoperiod may support higher NAMPT amplitude. Net tissue NAD+ likely rises modestly in healthy, UV-exposed individuals during peak summer months, potentially reducing the incremental benefit of supplemental NMN or NR.

Heat Stress and NAD+ Catabolism

Heat stress activates heat-shock proteins and mitochondrial stress pathways that consume NAD+ via SIRT3 and PARP-1. A rodent study showed that 3 hours of 37°C heat stress reduced hepatic NAD+ by roughly 25%, with NMN supplementation attenuating this decline. [9] Human data directly replicating this are absent, but athletes training in hot summer conditions represent a subgroup where higher NMN or NR doses (closer to 500 mg/day) may be justifiable.

Sun Exposure, Melanin, and Vitamin D Co-Supplementation

For individuals who achieve strong summer UV-B exposure, cutaneous vitamin D synthesis peaks between April and September at mid-latitudes. Vitamin D3 at physiologic concentrations (50 to 80 ng/mL 25-OH-D) supports NAMPT transcription through the VDR-RXR pathway. [6] Supplementing vitamin D3 (typically 2,000 to 4,000 IU/day adjusted to serum levels) alongside NMN in winter may sustain a portion of the NAMPT-activating signal that summer sunlight provides naturally.

Winter-Specific Protocol: Compounding Deficiencies

Winter at latitudes above 35°N typically brings three concurrent NAD+-suppressing factors: reduced photoperiod, lower UV-B (collapsing vitamin D synthesis), and often lower physical activity. Each of these independently reduces NAMPT activity or NAD+ consumption-driven salvage signaling.

The Vitamin D-NAMPT Intersection

Vitamin D deficiency affects an estimated 41.6% of U.S. Adults, with prevalence rising sharply in winter. [10] VDR agonism at the NAMPT promoter means that a person with 25-OH-D below 20 ng/mL may have structurally impaired NAMPT transcription, limiting the cell's ability to convert supplemental NMN into downstream NAD+ as efficiently as a vitamin D-replete individual. Correcting vitamin D deficiency before or alongside NMN/NR supplementation is a clinically logical step that likely enhances response, though direct combination RCTs are needed to confirm this.

Exercise as a Winter Countermeasure

Exercise independently induces NAMPT in skeletal muscle through AMPK activation. A 2014 study by Costford et al. Showed that a single 45-minute cycling bout at 70% VO2max increased skeletal muscle NAMPT protein by 127% above resting levels at 3 hours post-exercise in trained adults. [11] Combining NMN supplementation with morning resistance or aerobic training in winter delivers NMN alongside peak NAMPT induction, creating a mechanistic combination (two processes converging on the same enzyme, not an abstract business metaphor).

Recommended Winter Adjustments

Based on current pharmacokinetic and mechanistic data, a reasonable winter protocol includes:

• NMN 500 mg or NR 500 mg taken within 60 minutes of waking
• Vitamin D3 co-supplementation titrated to achieve 25-OH-D of 50 to 70 ng/mL
• Morning resistance or aerobic training within 2 hours of dosing when feasible
• Reassessment of 25-OH-D at 8 to 12 weeks to confirm repletion

No published RCT has tested this combined winter protocol directly. The framework draws from individual mechanistic studies, and physicians should counsel patients accordingly.

NMN Versus NR: Does Seasonality Shift the Preference?

NMN and NR enter the NAD+ salvage pathway at different points. NMN is converted directly by NMN adenylyltransferases (NMNATs) to NAD+. NR is first phosphorylated to NMN by nicotinamide riboside kinases (NRKs) before the same NMNAT step. In conditions of low NRK activity, such as aging muscle, NR's extra phosphorylation step may be rate-limiting. [12]

Aging Muscle in Winter: NMN's Potential Advantage

Older adults (age 60+) show reduced NRK1 and NRK2 expression in skeletal muscle compared to young adults. [12] In winter, when NAMPT activity is already suppressed and physical activity is lower, the extra enzymatic step NR requires may create a bottleneck. This is speculative extrapolation from in vitro data, but it provides a biologically grounded reason why NMN might be the preferred precursor for older adults during winter months, even though no head-to-head seasonal trial exists.

Cost-Adjusted Dosing by Season

NR is generally less expensive per gram than pharmaceutical-grade NMN. One practical approach: use NR 300 mg/day in summer when endogenous NAD+ production is relatively supported, and switch to NMN 500 mg/day in winter to bypass the NRK step. A clinician administering this protocol should document baseline and follow-up functional markers (fasting insulin, HbA1c, grip strength, or PROMIS fatigue score) to assess individual response across both phases.

Circadian Medicine Framework for Year-Round Dosing

The table below summarizes the seasonal dosing framework drawn from the mechanistic evidence reviewed above.

| Season | Photoperiod | Key NAD+ Pressure | Suggested Dose | Supporting Intervention | |---|---|---|---|---| | Winter (Dec-Feb, 35°+N) | Short | Low NAMPT, low VDR signaling | NMN 500 mg AM | Vitamin D3 titration, morning exercise | | Spring (Mar-May) | Lengthening | Recovering NAMPT amplitude | NMN/NR 250-500 mg AM | Light exposure 30 min AM | | Summer (Jun-Aug) | Long | PARP-1 activation, heat stress | NMN/NR 250-300 mg AM | Hydration, post-exercise dosing in athletes | | Fall (Sep-Nov) | Shortening | Metabolic insulin resistance peak | NMN 500 mg AM | HbA1c monitoring if pre-diabetic |

This framework is not an FDA-approved protocol. It synthesizes mechanistic and pharmacokinetic data; clinical validation through seasonal RCTs is needed before it can carry a grade-A recommendation.

Safety Across Seasons: What the Trial Data Confirm

All published human NMN and NR trials through 2024 with durations of 8 to 12 weeks have reported no serious adverse events. [5, 7, 13] The most common adverse effects are mild gastrointestinal symptoms (nausea, loose stools) reported in fewer than 10% of participants, typically at doses above 500 mg/day. No seasonal variation in adverse-event rates has been reported, though this is partly because no study has specifically tracked seasonal use.

The Methyl Donor Question

High-dose nicotinamide (a downstream metabolite of NMN/NR) competes with methylation pathways, consuming S-adenosylmethionine (SAMe). A theoretical concern exists that sustained high-dose NMN or NR supplementation (above 1,000 mg/day) could deplete methyl groups, with downstream effects on homocysteine. Healthy adults eating adequate protein and methyl donors (eggs, leafy greens, legumes) are unlikely to encounter this clinically. However, the risk is higher in winter when dietary quality often declines and B12/folate intake may drop. Checking plasma homocysteine at baseline and at 12 weeks in patients taking more than 500 mg/day is a reasonable precaution. [13]

Drug Interactions With Seasonal Context

NMN and NR have no confirmed pharmacokinetic drug-drug interactions in published human data. A theoretical interaction exists with PARP inhibitors (olaparib, niraparib), since PARP enzymes consume NAD+; co-administration could theoretically blunt the inhibitor's mechanism. Seasonal variation in this interaction has not been studied. Patients on PARP inhibitors for oncologic indications should not take NMN or NR without oncologist clearance, regardless of season.

Monitoring Markers for Seasonal Response Assessment

Tracking functional markers across seasonal transitions gives the prescribing clinician objective data to adjust dose rather than relying on patient-reported energy alone.

Recommended Laboratory Panel

At baseline and every 12 weeks:

• Fasting insulin and HOMA-IR (most sensitive to SIRT1/NAD+ changes per Yoshino et al. 2021)
• HbA1c (seasonal metabolic context)
• 25-OH-D (vitamin D status; target 50 to 70 ng/mL)
• Plasma homocysteine (methyl donor status at doses above 500 mg/day)
• Optional: whole-blood NAD+ (Bioanalytical Systems or ChromaDex methods; reference range roughly 18 to 28 nmol/mL in healthy adults)

Functional Assessments

Grip strength (dynamometry) and a validated fatigue instrument such as the PROMIS-Fatigue 7-item scale provide low-cost, repeatable signals of whether skeletal-muscle NAD+ metabolism is responding. The Yoshino trial showed a statistically significant improvement in insulin-stimulated glucose disposal (P<0.05 by hyperinsulinemic-euglycemic clamp) after 10 weeks of 250 mg/day NMN. [5] If a patient's HOMA-IR does not improve within 12 weeks on a stable winter protocol, dose escalation to 500 mg/day or switching from NR to NMN is justified.

Telehealth Prescribing Considerations

HealthRX clinicians writing NMN or NR regimens should document the following in the patient record:

1. Current latitude (seasonal UV-B relevance), current 25-OH-D level, and season of initiation.
2. Baseline HOMA-IR and HbA1c (especially for pre-diabetic or metabolic syndrome patients).
3. Planned dose and timing, with rationale for seasonal selection.
4. 12-week follow-up labs including 25-OH-D and fasting insulin.
5. Patient understanding that NMN and NR are supplements without FDA-approved indications, and that the seasonal framework described here has not been validated in dedicated seasonal RCTs.

The FDA does not regulate NMN or NR as approved drugs. In December 2022, the FDA stated that NMN cannot be marketed as a dietary supplement because it was first studied as a drug (IND 151019). That regulatory status is currently contested, and products remain commercially available. Clinicians should confirm the regulatory status of any specific NMN product before recommending it. [14]